CD39及其相关免疫检查点抑制剂在乳腺癌免疫治疗中的研究进展  

Research Progress of Biomarker CD39 and Immune Checkpoint Inhibitors in Immunotherapy of Breast Cancer

作　　者：张昱希 高凌[1] 吕庆福[1] ZHANG Yu-xi;GAO Ling;LV Qing-fu(Department of General Surgery,First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,215026,China)

机构地区：[1]苏州大学附属第一医院普外科,江苏苏州215026

出　　处：《中国血液流变学杂志》2024年第4期671-676,共6页Chinese Journal of Hemorheology

基　　金：国家自然科学基金资助项目(81974375)。

摘　　要：免疫检查点抑制剂(ICIs)能够下调T细胞活性,降低免疫抑制信号传递,属于潜在的乳腺癌治疗药物。CD39可与CD73协同作用,表达于免疫细胞表面,在CD8+T等免疫细胞及多种恶性肿瘤中表达上调,能够促进肿瘤转移和生长。提示CD39能够被视为一个免疫检查点,对CD39的抑制可能会提高肿瘤内免疫细胞比例和活性,从而增强肿瘤免疫。阻断CD39及其相关免疫检查点的联合免疫疗法可能是一种有希望的治疗策略。该研究将对生物标志物CD39及其相关ICIs的最新研究进行综述,从而为乳腺癌免疫治疗提供理论依据。As a possible medication for the treatment of breast cancer,immune checkpoint inhibitors(ICIs)have the ability to decrease immunosuppressive signaling and down-regulate T cell activity.CD39 can act synergistically with CD73 and is expressed on the surface of immune cells,and its expression is up-regulated in immune cells such as CD8+T and a variety of malignant tumors,which may encourage the growth and metastasis of tumors.It is suggested that CD39 can be regarded as an immune checkpoint,and the inhibition of CD39 may increase the proportion and activity of immune cells in tumor,thus enhancing tumor immunity.Combined immunotherapy that blocks CD39 and its associated immune checkpoints may be a promising treatment strategy.This study will review the latest research on the biomarker CD39 and its related ICIs,so as to provide theoretical basis for breast cancer immunotherapy.

关 键 词：免疫检查点抑制剂 乳腺癌 CD39 免疫治疗 免疫检查点 肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]